2' and 3'-nucleoside prodrugs for treating flaviviridae infections
CA 2490200 C · Owner: Centre National De La Recherche Scientifique · Inventors: Storer, Richard; Sommadossi, Jean-Pierre; La Colla, Paolo
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
2' and 3'-Prodrugs of l', 2', 3' or 4'-branched .szlig.-D or .szlig.-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. These modified nucleosides provide superior results against flaviviruses and pestiviruses including hepatitis C , virus and viruses generally that replicate through an RNA dependent RNA reverse transcriptase. Compounds, compositions methods and uses are provided , for the treatment of Flaviviridae infection including HCV infection, that , include the administration of an effective amount of the prodrugs of the present …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 27, 2003 and granted January 3, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 27, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 27, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.